ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery, announced today the appointment of Roy F. Waldron to its Board of Directors, effective immediately.
Mr. Waldron brings over 20 years of legal and intellectual property experience to ChemioCare. He recently retired from his role as Senior Vice President‚ Associate General Counsel and Chief Intellectual Property Counsel at Pfizer. There, he led global teams of Pfizer attorneys and professionals in procuring patents‚ and worked closely with R&D‚ Business Development and Pfizer Business Units to develop and strengthen intellectual property strategies for development and acquisition targets. He holds a JD from New York University Law School‚ a PhD from Yale and a BA from Dartmouth College.
“We are pleased to welcome Roy to our Board of Directors. His experience in developing, executing, and defending Intellectual property strategies at Pfizer will be invaluable as we continue to build our company” said Pedro Lichtinger, Chairman and CEO, “We expect to continue to strengthen the IP portfolio for our PETT platform and for each unique patch as they progress in their development process and generate novel data and findings”
Roy added, “As a firm believer that innovation is absolutely fundamental to delivering better healthcare to patients, I am thrilled to be part of a team prioritizing inventive technologies to solve longstanding drug delivery challenges.”
A biotechnology company focused on improving the profiles of medicines through its proprietary permeation enhanced transdermal technology (PETT). The platform technology uniquely combines high flux and sustained release into a matrix drug in adhesive patch. ChemioCare has 3 patches in development for cancer and cancer supportive care. Its lead programs are expected to enter phase 3 pivotal studies late 2019. Each product leverages the 505(b)2 regulatory path and is aiming at establishing improved efficacy, a new indication, and reduced or eliminated side effects from originator products.
To learn more, visit www.chemio.care
This press release contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of the business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward-looking statements by words such as “may,” “should,” “plan,” “intend,” “potential,” “continue,” “believe,” “expect,” “predict,” “anticipate” and “estimate,” the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward-looking statements. The forward-looking statements are qualified by their terms and/or important factors, many of which are outside the Company’s control, involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward-looking statements are based on the company’s beliefs, assumptions and expectations of future performance, taking into account information currently available to the Company. Neither the Company, nor any other person assumes responsibility for the accuracy or completeness of these statements. Information in this press release will be updated only to the extent required under applicable laws. If a change occurs, business, financial condition, liquidity and results of operations may vary materially for from those expressed in the aforementioned forward-looking statements.